4-(chloromethyl)-N,N-dimethylbenzamide | 121083-51-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(chloromethyl)-N,N-dimethylbenzamide
• CAS: 121083-51-0
• 化学式: C₁₀H₁₂ClNO
• mdl: MFCD11204892
• 分子量: 197.664
• InChiKey: UMAPDJRQFLVOIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)-N,N-dimethylbenzamide 在 1,1'-双(二苯基膦)二茂铁 、 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 sodium t-butanolate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 4-bromo-1-(4-(dimethylcarbamoyl)benzyl)-6-(tetrahydro-2H-pyran-4-ylthio)-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  [EN] HETEROARYL RHEB INHIBITORS AND USES THEREOF
  [FR] INHIBITEURS DE RHEB À BASE D'HÉTÉROARYLE ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物、其组合物以及使用方法。包括本发明的化合物或其药学上可接受的衍生物与药学上可接受的载体、辅料或载体组成的组合物。本发明组合物中的化合物的量使其能够在生物样本或患者中明显抑制Rheb。

  公开号：

  WO2018191146A1
• 作为产物：
  描述：

  对氯甲基苯甲酸 、 盐酸二甲胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.3h， 以90%的产率得到4-(chloromethyl)-N,N-dimethylbenzamide
  参考文献：
  名称：

  Simplifying Nickel(0) Catalysis: An Air-Stable Nickel Precatalyst for the Internally Selective Benzylation of Terminal Alkenes

  摘要：

  The synthesis and characterization of the air-stable nickel(II) complex trans-(PCy2Ph)(2)Ni(o-tolyl)Cl is described in conjunction with an investigation of its use for the Mizoroki-Heck-type, room temperature, internally selective coupling of substituted benzyl chlorides with terminal alkenes. This reaction, which employs a terminal alkene as an alkenylmetal equivalent, provides rapid, convergent access to substituted allylbenzene derivatives in high yield and with regioselectivity greater than 95:5 in nearly all cases. The reaction is operationally simple, can be carried out on the benchtop with no purification or degassing of solvents or reagents, and requires no exclusion of air or water during setup. Synthesis of the precatalyst is accomplished through a straightforward procedure that employs inexpensive, commercially available reagents, requires no purification steps, and proceeds in high yield.

  DOI：

  10.1021/ja3116718

文献信息

• Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases
  申请人：——

  公开号：US20010034343A1

  公开（公告）日：2001-10-25

  The present invention relates to novel 4-(1H-benzimidazol-2-yl)[1,4]diazepane derivatives of formula 1 and stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonist. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.

  本发明涉及一种新颖的4-(1H-苯并咪唑-2-基)[1,4]二氮杂环庚烷衍生物及其立体异构体，以及其药学上可接受的盐，其作为组胺受体拮抗剂和速激肽受体拮抗剂具有用途。这些拮抗剂在过敏性鼻炎的治疗中有用，包括季节性鼻炎和鼻窦炎；炎症性肠病，包括克罗恩病和溃疡性结肠炎；哮喘；支气管炎；以及呕吐。
• [EN] NICKEL PRE-CATALYSTS AND RELATED COMPOSITIONS AND METHODS<br/>[FR] PRÉ-CATALYSEURS DE NICKEL ET COMPOSITIONS ET MÉTHODES ASSOCIÉES
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2015070026A1

  公开（公告）日：2015-05-14

  Described herein are nickel pre-catalysts and related compositions and methods. The nickel pre-catalysts may be activated to form catalysts which may be utilized in organic reactions.

  本文描述了镍前催化剂及相关组成物和方法。这些镍前催化剂可以被活化形成催化剂，可用于有机反应中。
• Metal-Free Addition of Benzyl Halides to Aldehydes Using Super Electron Donors: Access to 3,4-Dihydroisocoumarins and 1,2-Diarylethanols
  作者：Cédric Spitz、Mélanie Matteudi、Guillaume Tintori、Julie Broggi、Thierry Terme、Patrice Vanelle

  DOI：10.1021/acs.joc.0c02374

  日期：2020.12.4

  We report here the intermolecular metal-free addition reaction of functionalized benzyl halides to aldehydes using a super electron donor (SED). The metal-free and mild conditions allowed the formation of 3,4-dihydroisocoumarins and 1,2-diarylethanols with unprecedented functional group tolerance.

  我们在这里报告使用超电子给体（SED）的官能化苄基卤化物与醛的无分子间金属加成反应。无金属且温和的条件允许形成具有前所未有的官能团耐受性的3,4-二氢异香豆素和1,2-二芳基乙醇。
• [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] AGENTS RECEPTEURS DE L'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005121080A1

  公开（公告）日：2005-12-22

  The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明公开了化合物I式或其药学上可接受的盐的新颖化合物，其具有组胺-H3受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一实施例中，本发明公开了包括化合物I式的药物组合物，以及使用这些组合物治疗肥胖症、认知缺陷、嗜睡病和其他组胺H3受体相关疾病的方法。
• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Beavers Lisa Selsam

  公开号：US20090118254A1

  公开（公告）日：2009-05-07

  The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明披露了公式I的新化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或反向激动剂活性，以及制备这些化合物的方法。在另一种实施方式中，本发明披露了包括公式I化合物的制药组合物，以及使用这些组合物治疗肥胖症、认知缺陷、嗜睡病和其他组胺H3受体相关疾病的方法。